Trial Profile
A Phase 1 Dose Escalation Study of SDX-7320 to Assess the Safety and Tolerability in Patients With Advanced Refractory or Late-Stage Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 May 2020
Price :
$35
*
At a glance
- Drugs Evexomostat (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors SynDevRx, Inc
- 28 Apr 2020 Results presented at the 111th Annual Meeting of the American Association for Cancer Research - I
- 22 Jan 2020 Status changed from recruiting to completed.
- 04 Apr 2019 Planned End Date changed from 1 Mar 2019 to 1 Mar 2020.